| Title |
Patterns of platinum drug use in an acute care setting: a retrospective study
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, May 2018
|
| DOI | 10.1007/s00432-018-2669-6 |
| Pubmed ID | |
| Authors |
Evangeline Armstrong-Gordon, Danijela Gnjidic, Andrew J. McLachlan, Bayan Hosseini, Andrew Grant, Philip J. Beale, Nial J. Wheate |
| Abstract |
Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions. A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015. Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia. The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 16% |
| Student > Master | 4 | 16% |
| Researcher | 3 | 12% |
| Student > Bachelor | 3 | 12% |
| Professor | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 8 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 10 | 40% |
| Engineering | 2 | 8% |
| Agricultural and Biological Sciences | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Medicine and Dentistry | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 9 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2018.
All research outputs
#16,049,105
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#1,504
of 2,632 outputs
Outputs of similar age
#212,385
of 331,511 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#15
of 30 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,511 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.